Literature DB >> 36051379

Temporal Trends in Internal vs. External Referrals for TAVR in a Large Academic Center: Patients Characteristics and Outcomes.

Aurelie Merlo1, Audrey Khoury1, Mohsin Shah1, Tabitha Linville2, John Ikonomidis1, Matthew Cavender2, John Vavalle2, Thomas Caranasos1.   

Abstract

Background: Since transcatheter aortic valve replacement (TAVR) first became approved for inoperable patients followed by high, intermediate-, and low-risk patients, referrals to TAVR centers have rapidly increased. The purpose of this study was to investigate referral patterns to a large academic TAVR center in the state of North Carolina and evaluate differences between externally and internally referred patients.
Methods: Data for all patients who underwent TAVR at our institution between November 2014 and March 2020 were pulled from the Transcatheter Valve Therapy Registry. The electronic medical record was used to determine the referral source. The descriptive statistical analysis was performed using Excel (Microsoft, Redmond, Washington).
Results: 491 patients underwent TAVR at our institution between November 2014 and March 2020. Half of the patients were referred by a cardiologist within the same health system (N = 250, 50.9%). Other referral sources included a cardiologist external to the health system (N = 210, N = 42.8%) and a surgeon or proceduralist (such as urologist, surgeon, or gastroenterologist) during the workup for another procedure (N = 26, 5.3%). Over time, there was a trend toward an increasing proportion of patients referred by a cardiologist external to our system, but this trend did not reach statistical significance (20.0% in 2014, 29.2% in 2015, 30.7% in 2016, 53.0% in 2017, 36% in 2018, 48.4% in 2019, and 56.8% in 2020, p=0.06 using the Mann-Kendall trend test). Externally referred patients were less likely to have private insurance and were more likely to have a reduced ejection fraction and had a higher mean gradient across the valve. Postprocedure, externally referred patients were more likely to have the procedure under moderate sedation and less likely to be discharged home. Conclusions: This study presents the referral pattern to a large TAVR center in North Carolina. Over time, there was an increase in external referrals suggesting that TAVR is increasingly adopted as an important component of the management of aortic valve stenosis. Internally and externally referred patients have differences in baseline demographic and clinical characteristics which may have an impact on clinical outcomes.
Copyright © 2022 Aurelie Merlo et al.

Entities:  

Mesh:

Year:  2022        PMID: 36051379      PMCID: PMC9410986          DOI: 10.1155/2022/6074368

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   1.776


1. Introduction

The advent of transcatheter technologies has revolutionized the field of aortic valve surgery, initially in high-risk patients and now extending in lower-risk patient populations. Transcatheter aortic valve replacement (TAVR) was first described in 2002 for a patient with critical aortic stenosis who had been declared inoperable [1], and yet the patient experienced an excellent result. This first in human experience sparked a rapid investigation into and development of TAVR technology. Since the initial trials, the indication for TAVR has expanded from inoperable patients and high-risk patients with the PARTNER trial in 2010 [2], to intermediate-risk patients with the PARNER2 and SURTAVI trials in 2016–2017 [3, 4], and finally to low-risk patients with the PARTNER3 and EVOLUT trials in 2019 (5, 6). One of the reasons for this expeditious evolution of technology is due to the remarkable outcomes that TAVR valves can offer. The latest trials in low-risk patients demonstrate freedom from the composite endpoint of death/stroke/rehospitalization of 91% [5] at one year and freedom from death/disabling stroke of 94% at one year [6]. Most modern series describe a length of stay of two to six days [7-9]. With the aforementioned outcomes and expansion of approval for TAVR in low-risk patients, heart centers across the country now offer TAVR as part of the armamentarium for addressing severe aortic stenosis. Within this context, referrals to TAVR centers have also increased [10], and in some countries, such as Canada, the surge in referrals has resulted in long waitlists to undergo the procedure [11]. Unfortunately, referral patterns to large TAVR centers are not well studied or understood. Understanding these referral patterns is critical for understanding factors related to program growth and addressing areas for targeted improvement in program outreach. The purpose of this study was to define referral patterns to a large academic TAVR center in the state of North Carolina and determine if there were demographic or clinical differences between internally referred and externally referred patients.

2. Methods

All patients who underwent TAVR at the University of North Carolina (UNC) between November 2014 and March 2020 were included in this study. All TAVR patients were entered into our institution's Transcatheter Valve Therapy (TVT) Registry database. This datafile was extracted from the online database and we performed a retrospective chart review of all patients to determine the referral source. The referral source was categorized as internal cardiologist, external cardiologist, procedure, self, or unknown. External cardiologist was defined as a cardiologist who does not work within the UNC hospital system. Procedure referral was defined as any patient who was referred for TAVR evaluation during the workup for another procedure, such as kidney transplant, colonoscopy, or urethral stent placement. All data extraction was conducted within the standard of our hospital's Institutional Review Board Committee (Study number 20-0606). The requirement for consent from individual study participants was waived given the retrospective nature of this chart review. Excel (Microsoft, Redmond, Washington) was used to perform descriptive and comparative statistical analysis, and the Mann–Kendall test was used to analyze temporal trends. T-tests and proportion tests were used to compare externally and internally referred patients. A p value < 0.05 was considered statistically significant.

3. Results

3.1. Study Population

491 patients underwent TAVR at our institution between November 2014 and March 2020. Baseline characteristics (Table 1) of the study population are noted in Table 1. The median patient age was 80.5 years, and the majority of patients were white (81.1%) and privately insured (66.2%). The most common comorbidities were hypertension (89.2%), atrial fibrillation (34.0%), and diabetes (39.1%). The average STS risk score was 5.5, 76% of patients had New York Heart Association Class III and IV, and 16% of patients had an ejection fraction less than 40%. 4% of patients had bicuspid aortic valves and the mean annulus size was 24.6 mm, the average valve area was 0.74 cm2, and the mean gradient across the valve was 41.8 mmHg. Externally referred patients were less likely to have insurance, but the remainder of the demographic factors were similar between groups. Externally referred patients were also more likely to have a reduced ejection fraction and a higher peak gradient across the aortic valve preprocedure.
Table 1

Patient characteristics of 491 consecutive patients undergoing TAVR at a single institution.

AllInternalExternalOthers p value
N/%25021031
Age (years)80.58180730.51
Male51%52%53%29%0.90
White81%80%81%84%0.89
Black15%15%16%13%0.87
Private insurance66%73%60%55%<0.01
Peripheral arterial disease20.4%20%21%16%0.88
Smoker9.8%8%10%13%0.56
Hypertension89.2%88%91%87%0.34
Diabetes39.1%38%40%39%0.73
Dialysis4.5%4%3%16%0.74
Home oxygen7.9%6%10%6%0.16
Hostile chest2.9%2%3%6%0.70
Immunosuppression4.9%6%3%6%0.18
Prior myocardial infarction13.0%12%15%9%0.42
Porcelain aorta2.6%4%1%3%0.07
Atrial fibrillation/flutter34.0%34%34%26%1.00
STS Risk score5.55.75.44.20.53
Body mass index28.826.427270.38
NYHA class III + IV76%76%76%66%1.00
Preprocedure hemoglobin12.012.112.111.80.74
Preprocedure creatinine1.081.031.040.80.19
% Ejection fraction <40%16%0%20%3%<0.01
Moderate or severe aortic insufficiency17%18%15%20%0.45
Bicuspid aortic valve4%5%3%3%0.34
Peak velocity (meter/second)4.064.014.094.270.29
Annulus size (mm)24.624.624.623.81.00
Aortic valve area (cm2)0.740.740.730.810.52
Aortic valve gradient (peak)41.840.543.143.30.03

The p value is in reference to comparison between internal and external referrals.

3.2. Procedure/Patient Characteristics

The majority of TAVR implantations were performed with moderate sedation (60.9%) and 6.1% were valve-in-valve implantations (Table 2). Postimplantation hemodynamics included an average postprocedure gradient of 5.4 mmHg, aortic valve area of 1.9 cm2, and maximum velocity of 2.2 m2; only 2% of patients had moderate or severe aortic regurgitation postprocedure. 98% of patients survived to discharge and 86% of patients were discharged home.
Table 2

Procedural outcomes of 491 consecutive patients undergoing TAVR.

AllInternalExternalOthers p value
Valve in valve6%6%6%3%1.00
Moderate sedation61%56%66%56%0.03
Postmean gradient (mmHg)5.45.25.56.20.80
Post-AVA (cm2)1.91.91.91.70.79
Postmaximum velocity (m2)2.22.22.22.30.40
Moderate or severe aortic insufficiency2%2%2%7%1.00
Alive discharge98%99%97%100%0.24
Discharge home86%89%80%100%0.01

The p value is in reference to comparison between internal and external referrals.

Patients who were externally referred were more likely to have the procedure performed under moderate sedation (rather than general anesthesia), but they were less likely to be discharged home. The remainder of the postprocedure hemodynamic parameters were similar between groups.

3.3. Referral Pattern

Approximately half of the patients were referred by a cardiologist within the same health system (N = 250, 50.9%) (Table 3). Other referral sources included a cardiologist external to the health system (N = 210, N = 42.8%) or a proceduralist during the workup for another procedure (N = 26, 5.3%). Three patients were self-referred and two patients had an unknown source of referral. Over time, there seemed to be a trend toward a higher proportion of referrals being made by cardiologists external to our system, but this trend was not statistically significant (20.0% in 2014, 29.2% in 2015, 30.7% in 2016, 53.0% in 2017, 36% in 2018, 48.4% in 2019, and 56.8% in 2020, p=0.06 using Mann–Kendall trend test) (Figure 1). One explanation for the decrease in referrals in 2018 is that hospital systems underwent a merger impacting internal and external referrals during that year, causing a reclassification of internal and external referring providers. When we repeated the Mann–Kendall test excluding the data from 2018, the trend toward an increase in external referrals was significant (p=0.024).
Table 3

Referral patterns for 491 patients undergoing TAVR at a single institution.

2014201520162017201820192020Total
External cardiologist120.0%729.2%2330.7%5353.0%4636.0%5948.4%2156.8%210
Internal cardiologist360.0%1458.3%4661.3%4040.0%7457.8%6049.2%1335.1%250
Procedure00.0%312.5%56.7%55.0%86.3%32.5%25.4%26
Self120.0%00.0%00.0%11.0%00.0%00.0%12.7%3
Unknown00.0%00.0%11.3%11.0%00.0%00.0%00.0%2
Total5247510012812237491
Figure 1

Referral source by year for all TAVRs performed at a single institution.

3.4. Referral during Workup for Another Procedure

Twenty-six patients (5.3%) were referred during the workup to undergo another procedure. The details regarding that referral process are included in Table 4. Nearly half of these patients were able to undergo their initial procedure within a year of undergoing TAVR (N = 12, 46.2%) (Table 4).
Table 4

Subset of patients referred by proceduralists and procedural outcomes.

Referral procedureUnderwent referral procedureUnderwent referral procedure within 1 yearComment
Surgery for endometrial cancerYesYes
Melanoma excisionYesYes
Ureteral stent placementYesYes
Kidney transplantNoNoHad kidney transplant >1 year after referral
Gastric outlet obstruction requiring surgeryYesYesEGD
Inguinal herniaUnknownLost to follow-up
Lung resection vs. SBRTYesYesSBRT
ColonoscopyUnknownLost to follow-up
Chemotherapy and radiation for lung cancerYes
Kidney transplantNoListed for kidney transplant
Shoulder surgeryNo
WhippleNoPatient elected to not have surgery
Parastomal herniayesYes
CholecystectomyYesYes
Kidney transplantYesYes
Removal breast implantYesYes
Ventral hernia repairYesYes
NephrectomyYesNo
ColonoscopyYesNo
Parastomal herniaYesYes
Partial nephrectomyYesNo
Ovarian massNo
Upper endoscopyNo
Colovesicular fistula takedownNoRequired DAPT that could not be discontinued
FEVARYesYes
Liver transplantNoHas not been a year

DAPT, dual antiplatelet therapy; EGD, esophagogastroduodenoscopy; FEVAR, fenestrated endovascular aortic repair; SBRT, stereotactic body radiation therapy.

4. Discussion

This study describes the referral patterns at a large academic TAVR center. Notable findings include that approximately half of all referrals originated from a cardiologist within the same hospital system and five percent of referrals came from a proceduralist. The ratio of referrals from internal versus external cardiologists has remained relatively stable over time, with a nonstatistically significant trend toward an increase in referrals from external cardiologists over time. We did see a statistically significant trend when excluding the data from the year 2018 during which the hospital system was undergoing a merger with another TAVR center. These findings may indicate a trend toward increased adoption of TAVR technology in the community. In addition, this study demonstrates that externally referred patients are less likely to have insurance. This is consistent with referrals made to public hospitals. Notably externally referred patients were also more likely to have a reduced ejection fraction and a higher peak gradient. This may be related to different standards within the cardiologists at our institution and in the community regarding the timing of referral to TAVR, or may demonstrate a later presentation to care in this population that was less likely to have a private insurance. The impact of the differences in presentation on clinical outcomes is unclear. The fact is that more externally referred patients who underwent the procedure with moderate sedation may be related to the increase in external referrals over time or may be related to the higher proportion of these patients having a reduced ejection fraction preoperatively. It is likely that the reduced proportion of patients discharged home who were referred externally is related to the reduced number of private insurance and a sicker presentation, but the exact causal mechanism is not clear. The findings of this study have been replicated in other studies. An analysis by Buchanan et al. demonstrated that the rate of TAVR exclusion has decreased by half over a six-year period in their institution [10]. An analysis of the Healthcare Cost and Utilization Project state inpatient databases in the states of Arizona, Florida, Iowa, Massachusetts, and Washington may suggest a mechanism as the authors demonstrated that patients treated at high-competition hospitals had higher odds of receiving TAVR, relative to patients at low-competition hospitals [12]. The majority of TAVR patients at our institution were white and privately insured patients. The gender breakdown was equal in our cohort, which is becoming more common in recent single institution TAVR studies [13, 14] (in contrast to the male predominance noted in early studies [15]). The most common comorbidities were hypertension, diabetes, and atrial fibrillation, which are again comorbidities frequently seen in other studies. While the majority of the patients in this cohort were white (80%), this is lower than the white predominance of 90% frequently reported at other centers [12, 13] if reported at all [16]. These referral patterns need to be implemented within the healthcare environment of North Carolina. The state includes sixteen TAVR centers (Table 5), many of which have opened in the past two to three years. Other contributors include market trajectories that are difficult to identify, such as hospital mergers and changes in referral groups.
Table 5

List of TAVR centers in North Carolina.

Hospital nameLocationCountyBedsTrauma designationTAVR
Atrium Health CabarrusConcordCabarrus447Level IIIYes
Atrium Health Carolinas Medical CenterCharlotteMecklenburg874Level IYes
Cape Fear Valley Medical CenterFayettevilleCumberland600Level IIIYes
CarolinaEast Medical CenterNew BernCraven350Yes
Cone Health Moses Cone HospitalGreensboroGuilford536Level IIYes
Duke University HospitalDurhamDurham943Level IYes
FirstHealth Moore Regional HospitalPinehurstMoore402Yes
Mission HospitalAshevilleBuncombe763Level IIYes
New Hanover Regional Medical CenterWilmingtonNew Hanover798Level IIYes
Novant Health Forsyth Medical CenterWinston-SalemForsyth921Yes
Novant Health Presbyterian Medical CenterCharlotteMecklenburg622Level IIIYes
UNC Medical CenterChapel HillOrange778Level IYes
UNC REX HospitalRaleighWake665Yes
Vidant Medical CenterGreenvillePitt974Level IYes
Wake Forest Baptist Medical CenterWinston-SalemForsyth885Level IYes
WakeMedRaleighWake567Level IYes
A particular interest of our study was to consider patients who were referred for TAVR during the workup for another procedure, and we were interested in discovering if these patients underwent that procedure within the first year after TAVR. We did note that 5.3% of referrals were from proceduralists, and close to half of these patients (46.2%) underwent their referral procedure within a year after TAVR. Furthermore, two of those patients were listed for kidney transplant within a year even if they did not undergo a transplant, and another patient elected to not have surgery. This study provides further evidence of the benefit to patients of the minimally invasive nature of TAVR and the shorter recovery time, allowing patients to undergo procedures within a year after TAVR.

4.1. Limitations

This study contains all of the limitations of a large retrospective chart review, even with the majority of the data collection (regarding patient and procedure characteristics) being performed by a dedicated clinical research coordinator using well-established definitions put forth via the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry. The additional data collection for referral patterns was simple and involved determining the referring source. Additionally, this study was not powered to analyze temporal trends in referral patterns. It is important to note that, since data collection for the years 2014 and 2020 were not full years, raw numbers could not be used for the analysis. Unfortunately, the time from when the referral was placed to the time of the procedure was not available with our dataset. It is possible that a difference in timing of workup and timing of procedure between externally referred patients and internally referred patients is contributing to the differences in outcomes. If there is a referral made to the heart valve center, all needed studies are scheduled the same day. It is rare that patients need an additional visit prior to deciding whether TAVR is needed. Nonetheless, delays in procedure timing or in referring patients are not accounted for in this analysis. Finally, additional data from other imaging modalities such as computed tomography calcium scoring and dobutamine stress echocardiography were not collected in this dataset. These are valuable assets in the evaluation of patients with severe aortic stenosis. Given that this information was unavailable for all patients, its availability would likely not impact the differences between externally and internally referred patients but could provide additional insight into the clinical outcomes of these patients, especially when compared to other institutions.

5. Conclusion

In summary, this article describes referral patterns at a large academic TAVR center and demonstrates key differences between externally and internally referred patients. In order to remain relevant in a state with a rapid growth of TAVR centers, targeted areas for this center to expand include outreach efforts to increase referrals from cardiologists outside of the health system, and also attempting to receive referrals for these patients earlier in the disease process. Furthermore, increasing internal referrals through referrals from proceduralists who are working up patients for other procedures may be another area to focus on. Finally, our center, a quaternary care hospital, may have a lower percentage of self-referrals, when compared to a community-based program.
  16 in total

1.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.

Authors:  Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

2.  Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.

Authors:  Jeffrey J Popma; G Michael Deeb; Steven J Yakubov; Mubashir Mumtaz; Hemal Gada; Daniel O'Hair; Tanvir Bajwa; John C Heiser; William Merhi; Neal S Kleiman; Judah Askew; Paul Sorajja; Joshua Rovin; Stanley J Chetcuti; David H Adams; Paul S Teirstein; George L Zorn; John K Forrest; Didier Tchétché; Jon Resar; Antony Walton; Nicolo Piazza; Basel Ramlawi; Newell Robinson; George Petrossian; Thomas G Gleason; Jae K Oh; Michael J Boulware; Hongyan Qiao; Andrew S Mugglin; Michael J Reardon
Journal:  N Engl J Med       Date:  2019-03-16       Impact factor: 91.245

3.  Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.

Authors:  Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith
Journal:  N Engl J Med       Date:  2019-03-16       Impact factor: 91.245

4.  The Effect of Hospital Market Competition on the Adoption of Transcatheter Aortic Valve Replacement.

Authors:  Raymond J Strobel; Donald S Likosky; Alexander A Brescia; Karen M Kim; Xiaoting Wu; Himanshu J Patel; G Michael Deeb; Michael P Thompson
Journal:  Ann Thorac Surg       Date:  2019-08-05       Impact factor: 4.330

5.  Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Michael J Reardon; Nicolas M Van Mieghem; Jeffrey J Popma; Neal S Kleiman; Lars Søndergaard; Mubashir Mumtaz; David H Adams; G Michael Deeb; Brijeshwar Maini; Hemal Gada; Stanley Chetcuti; Thomas Gleason; John Heiser; Rüdiger Lange; William Merhi; Jae K Oh; Peter S Olsen; Nicolo Piazza; Mathew Williams; Stephan Windecker; Steven J Yakubov; Eberhard Grube; Raj Makkar; Joon S Lee; John Conte; Eric Vang; Hang Nguyen; Yanping Chang; Andrew S Mugglin; Patrick W J C Serruys; Arie P Kappetein
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Albumin Is Predictive of 1-Year Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Katherine R Hebeler; Heike Baumgarten; John J Squiers; Jordan Wooley; Benjamin D Pollock; Cecile Mahoney; Giovanni Filardo; Brian Lima; J Michael DiMaio
Journal:  Ann Thorac Surg       Date:  2018-07-23       Impact factor: 4.330

7.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

8.  Single center TAVR experience with a focus on the prevention and management of catastrophic complications.

Authors:  Samir R Kapadia; Lars G Svensson; Eric Roselli; Paul Schoenhagen; Zoran Popovic; Andrej Alfirevic; Benico Barzilai; Amar Krishnaswamy; William Stewart; Anand Mehta; Kanhaiya Lal Poddar; Akhil Parashar; Dhruv Modi; Alper Ozkan; Umesh Khot; Bruce W Lytle; E Murat Tuzcu
Journal:  Catheter Cardiovasc Interv       Date:  2014-02-03       Impact factor: 2.692

9.  Short Length of Stay After Elective Transfemoral Transcatheter Aortic Valve Replacement is Not Associated With Increased Early or Late Readmission Risk.

Authors:  Maneesh Sud; Feng Qui; Peter C Austin; Dennis T Ko; David Wood; Andrew Czarnecki; Vaidehi Patel; Douglas S Lee; Harindra C Wijeysundera
Journal:  J Am Heart Assoc       Date:  2017-04-24       Impact factor: 5.501

10.  Impact of procedural capacity on transcatheter aortic valve replacement wait times and outcomes: a study of regional variation in Ontario, Canada.

Authors:  Kayley A Henning; Mithunan Ravindran; Feng Qiu; Neil P Fam; Tej N Seth; Peter C Austin; Harindra C Wijeysundera
Journal:  Open Heart       Date:  2020-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.